Mangalam Drugs and Organics Ltd
NSE:MANGALAM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Mangalam Drugs and Organics Ltd
Cash from Operating Activities
Mangalam Drugs and Organics Ltd
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Mangalam Drugs and Organics Ltd
NSE:MANGALAM
|
Cash from Operating Activities
₹183.9m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Cash from Operating Activities
₹58.8B
|
CAGR 3-Years
12%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Cash from Operating Activities
₹42.9B
|
CAGR 3-Years
14%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Cash from Operating Activities
₹127.2B
|
CAGR 3-Years
46%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
Lupin Ltd
NSE:LUPIN
|
Cash from Operating Activities
₹47.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
146%
|
CAGR 10-Years
N/A
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Cash from Operating Activities
₹19.4B
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
Mangalam Drugs and Organics Ltd
Glance View
Mangalam Drugs & Organics Ltd. engages in the manufacture of drugs, medicines and allied products. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2005-05-26. The firm handles marketing in both domestic and export markets. The firm is also engaged in the Fight Malaria program for the supply of anti-malarial APIs worldwide. Its API products include Acyclovir, Amodiaquine HCI, Artemether, Artesunate, Atazanavir Sulfate, Atorvastatin Calcium, Bisoprolol Fumarate and Furosemide. Its intermediates products include 4,6-Dichloro-5-Methoxy Pyrimidine, 2-Dibutylamino-1-Ethanol (DBA), 4,7- Dichloroquinoline, Ortho Phenoxy Methane Sulfonanilide, Tenofovir Alafenamide Base and Tenofovir Disoproxil Base. The company also offers specialty chemicals, such a L (+)-Menthol, 2,3 Dihydrophthalazine-1,4-dione, 4-Cynoethyl-2- Methyl Phenol. The firm offers its products to Italy, Russia, China, Turkey, Nigeria, Uganda, Kenya and Pakistan. The company has two multi-product manufacturing facilities located at Vapi, district Valsad, Gujarat.
See Also
What is Mangalam Drugs and Organics Ltd's Cash from Operating Activities?
Cash from Operating Activities
183.9m
INR
Based on the financial report for Dec 31, 2025, Mangalam Drugs and Organics Ltd's Cash from Operating Activities amounts to 183.9m INR.
What is Mangalam Drugs and Organics Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
-13%
Over the last year, the Cash from Operating Activities growth was -49%. The average annual Cash from Operating Activities growth rates for Mangalam Drugs and Organics Ltd have been -13% over the past three years .
